Bandoo C Chatale¹*, Madhuri B Goswami¹, Akshata Yashwant Patne², Bhairavi Murkute¹, Swati Mutha³, and Kashmira R Chaudhari¹

¹MET Institute of Pharmacy (Degree), MET Complex, Bandra Reclamation, Bandra (West), Mumbai, India
²Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA
³School of Pharmacy, Vishwakarma University, Pune, India

*Corresponding Author: Bandoo C Chatale, Assistant Professor, MET Institute of Pharmacy (Degree), MET Complex, Bandra Reclamation, Bandra (West), Mumbai, India.

Received: January 07, 2025; Published: February 28, 2025

Abstract

In the relentless pursuit to control COVID-19, a diverse range of therapies has been under investigation, each with the potential for significant impact on the course of the pandemic. This review meticulously collates and examines data on these proposed treatments, highlighting the need for further drug development and clinical trials to enable their effective use in combating the virus. The potential medications discussed are RNA mutagens, virus entry and release blockers, and protease inhibitors. Additionally, this review provides a comprehensive overview of the mechanisms behind the currently available vaccines, offering insights into their role in fighting against the SARS-CoV-2 virus. This virus, identified as a single-stranded RNA beta-coronavirus, is notable for its complex genome that codes for accessory, non-structural, and structural proteins and for the emergence of new strains that pose ongoing challenges. The pervasive impact of SARS-CoV-2, characterized by its high transmissibility and capacity to induce widespread panic, underscores the urgency of addressing this global health crisis. The review advocates for policy shifts to prioritize the administration of booster doses to populations at heightened risk, including those with compromised immune systems, existing comorbidities, and other vulnerabilities, as a strategy to mitigate the severity of COVID-19 outcomes.

Keywords:Coronavirus; Clinical Trials; Drug Repurposing; Vaccine Development; COVID-19; Side Effects

References

1. Hemeg HA. “Variation of Omicron from COVID-19: A Review”. Cardiometry 26 (2023): 187-197.
2. Mir T., et al. “Coronavirus disease 2019 (COVID-19): Multisystem review of pathophysiology”. Annals of Medicine and Surgery 69 (2021): 102745.
3. Gupta A., et al. “Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview”. Clinical and Experimental Medicine2 (2023): 313-331.
4. Liu Y C., et al. “COVID-19: The first documented coronavirus pandemic in history”. Biomed Journal4 (2020): 328-333.
5. Cucinotta D and Vanelli M. “WHO Declares COVID-19 a Pandemic”. Acta Biomed1 (2020): 157-160.
6. Faria NR., et al. “Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil”. Science 6544 (2021): 815-821.
7. Arya R., et al. “Structural insights into SARS-CoV-2 proteins”. Journal of Molecular Biology 2 (2021): 166725.
8. Kadam S B., et al. “SARS‐CoV‐2, the pandemic coronavirus: Molecular and structural insights”. Journal of Basic Microbiology3 (2021): 180-202.
9. Cimolai N. “In pursuit of the right tail for the COVID-19 incubation period”. Public Health 194 (2021): 149-155.
10. Chowdhury ATMM., et al. “Analysis of the primary presenting symptoms and hematological findings of COVID-19 patients in Bangladesh”. The Journal of Infection in Developing Countries2 (2021): 214-223.
11. Cui N., et al. “Preliminary CT findings of coronavirus disease 2019 (COVID-19)”. Clinical Imaging 65 (2020): 124-132.
12. Baj J., et al. “COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge”. Journal of Clinical Medicine6 (2020).
13. Chen X., et al. “A systematic review of neurological symptoms and complications of COVID-19”. Journal of Neurology 268 (2021): 392-402.
14. Munir K., et al. “Zoonotic and reverse zoonotic events of SARS-CoV-2 and their impact on global health”. Emerging Microbes and Infections1 (2020): 2222-2235.
15. Du L., et al. “The spike protein of SARS-CoV--a target for vaccine and therapeutic development”. Nature Reviews Microbiology3 (2009): 226-236.
16. Kumar A., et al. “The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?” Expert Review of Vaccines8 (2022): 1071-1086.
17. Dash P., et al. “A scoping insight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel coronavirus (COVID-19. pandemic-a comprehensive review”. Frontiers in Pharmacology 11 (2021): 590154.
18. Mulligan MJ., et al. “Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults”. Nature 7830 (2020): 589-593.
19. Alsafi R T. “Lessons from SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 Infections: What We Know So Far”. Canadian Journal of Infectious Diseases and Medical Microbiology1 (2022): 1156273.
20. Ng Y L., et al. “Drug repurposing for COVID-19: Approaches, challenges and promising candidates”. Pharmacology Therapy 228 (2021): 107930.
21. Nyarko RO., et al. “A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review”. (2020).
22. Moumbock A F., et al. “BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry”. Archiv der Pharmazie1 (2023): 2200371.
23. Zhu W., et al. “RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery”. SLAS Discovery10 (2020): 1141-1151.
24. Furuta Y., et al. “Favipiravir (T-705 a broad spectrum inhibitor of viral RNA polymerase”. Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences7 (2017): 449-463.
25. Tong S., et al. “Ribavirin therapy for severe COVID-19: a retrospective cohort study”. International Journal of Antimicrobial Agents3 (2020): 106114.
26. Talha B and Dhamoon A S. Ritonavir (2019).
27. Dorward J., et al. “The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review”. Antiviral Therapy7 (2020): 365-376.
28. Rattanapisit K., et al. “Rapid production of SARS-CoV-2 receptor binding domain (RBD. and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana”. Scientific Reports1 (2020): 17698.
29. Iacob S., et al. “SARS-coV-2 treatment approaches: numerous options, no certainty for a versatile virus”. Frontiers in Pharmacology 11 (2020): 1224.
30. Felsenstein S., et al. “COVID-19: Immunology and treatment options”. Clinical Immunology 215 (2020): 108448.
31. Chen C., et al. “Favipiravir versus arbidol for COVID-19: a randomized clinical trial”. MedRxiv (2020): 2020.2003. 2017.20037432.
32. Li Y., et al. “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”. Mbio5 (2023): e01273-01223.
33. Saha A., et al. “Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19”. Archives of Medical Research6 (2021): 595-597.
34. Ahmed MH and Hassan A. “Dexamethasone for the treatment of coronavirus disease (COVID-19): a review”. SN Comprehensive Clinical Medicine 12 (2020): 2637-2646.
35. Hashem AM., et al. “Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review”. Travel Medicine and Infectious Disease 35 (2020): 101735.
36. Lamers M M., et al. “SARS-CoV-2 pathogenesis”. Nature Reviews Microbiology 5 (2022): 270-284.
37. Jafarzadeh A., et al. “Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions”. Life Sciences 257 (2020): 118102.
38. Gianoli S. “Infection of macrophages by SARS-CoV-2: implications for viral spreading and immune response”. (2023).
39. Sullivan H C and Roback J D. “Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic”. Transfusion Medicine Reviews3 (2023): 145-150.
40. Zhang R., et al. “COVID-19: Melatonin as a potential adjuvant treatment”. Life Science 250 (2020): 117583.
41. Shannon A., et al. “Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase”. bioRxiv (2020).
42. Magro P., et al. “Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment”. Biomed Journal1 (2021): 43-53.
43. Liu X., et al. “Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study”. Trials1 (2020): 622.
44. Arshad S., et al. “Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19”. International Journal of Infectious Diseases 97 (2020): 396-403.
45. Yuan J., et al. “Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS”. Drugs Real World Outcomes 8.2 (2021): 131-140.
46. Lampejo T. “Influenza and antiviral resistance: an overview”. European Journal of Clinical Microbiology and Infectious Diseases 7 (2020): 1201-1208.
47. Zizzo G., et al. “Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling”. Frontiers in Immunology 13 (2020): 795315.
48. Pimentel L G., et al. “Association between Glucose Levels and Intraocular Pressure: Pre- and Postprandial Analysis in Diabetic and Nondiabetic Patients”. Journal of Ophthalmology 2015 (2015): 832058.
49. Harrison SC. “Mechanism of membrane fusion by viral envelope proteins”. Advances in Virus Research 64 (2005): 231-261.
50. Sun J., et al. “Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19”. World Journal of Clinical Cases10 (2023): 2168-2180.
51. Kip KE., et al. “Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.” Annals of Internal Medicine4 (2023): 496-504.
52. Cox M., et al. “SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies”. Nature Reviews Microbiology2 (2023): 112-124.
53. Ndwandwe D and Wiysonge CS. “COVID-19 vaccines”. Current Opinion in Immunology 71 (2021): 111-116.
54. Kashte S., et al. “COVID-19 vaccines: rapid development, implications, challenges and future prospects”. Human Cell3 (2021): 711-733.
55. Mahase E. “Covid-19: Russia approves vaccine without large scale testing or published results”. BMJ: British Medical Journal (Online) 370 (2020): m3205.
56. Juncker HG., et al. “Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands”. EClinicalMedicine (2022): 47.
57. Kumar VM., et al. “Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases”. npj Vaccines1 (2021): 60.
58. Demongeot J and Fougère, C. “mRNA COVID-19 Vaccines-Facts and Hypotheses on Fragmentation and Encapsulation”. Vaccines (Basel)1 (2022).
59. Chavda VP., et al. “Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status”. Vaccines (Basel)2 (2023).
60. Donaldson B., et al. “Virus-like particle vaccines: immunology and formulation for clinical translation”. Expert Reviews Vaccines9 (2018): 833-849.
61. Chavda V P., et al. “mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!” Vaccines (Basel)3 (2023).
62. Chenchula S., et al. “Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review”. Journal of Medical Virology7 (2022): 2969-2976.
63. Korves C., et al. “Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis”. Vaccine33 (2022): 4742-4747.
64. Lusvarghi S., et al. “SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster”. bioRxiv (2021).
65. Pérez-Then E., et al. “Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination”. Nature Medicine3 (2022): 481-485.
66. Atmar R L., et al. “Homologous and Heterologous Covid-19 Booster Vaccinations”. The New England Journal of Medicine11 (2022): 1046-1057.
67. Faksova K., et al. “COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN. cohort study of 99 million vaccinated individuals”. Vaccine29 (2024): 2200-2211.
68. Soboleva K., et al. “Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19. Vaccination”. Lancet Global Health1 (2022): e33-e34.
69. Jhaj R., et al. “Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines”. Vaccines (Basel)12 (2022).
70. Chenchula S., et al. “Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review”. Virology 584 (2023): 38-43.
71. Firouzabadi N., et al. “Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2”. International Immunopharmacology 117 (2023): 109968.
72. Alshahrani M M and Alqahtani A. “Side Effects of Mixing Vaccines against COVID-19 Infection among Saudi Population”. Vaccines (Basel)4 (2022).
73. Rundle CW., et al. “Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society”. Journal of the American Academy of Dermatology 6 (2020): 1730-1737.
74. Ayouni I., et al. “Effective public health measures to mitigate the spread of COVID-19: a systematic review”. BMC Public Health1 (2021): 1015.
75. Pan L., et al. “Prevention and control of coronavirus disease 2019 (COVID-19. in public places”. Environmental Pollution 292 (2022): 118273.
76. Rabaan A A., et al. “Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences”. Medicina (Kaunas)3 (2023).
77. Mahilkar S., et al. “SARS-CoV-2 variants: Impact on biological and clinical outcome”. Frontiers in Medicine (Lausanne) 9 (2022): 995960.
78. Geoghegan J L., et al. “Virological factors that increase the transmissibility of emerging human viruses”. Proceedings of the National Academy of Sciences of the United States of America15 (2015): 4170-4175.
79. Liang F. “Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest”. Viruses5 (2023).
80. Cosar B., et al. “SARS-CoV-2 Mutations and their Viral Variants”. Cytokine Growth Factor Review 63 (2022): 10-22.
81. Tian D., et al. “The global epidemic of SARS-CoV-2 variants and their mutational immune escape”. Journal of Medical Virology3 (2022): 847-857.
82. Tao K., et al. “The biological and clinical significance of emerging SARS-CoV-2 variants”. Nature Review Genetics12 (2021): 757-773.
83. Han N., et al. “Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies”. Science Advances 27 (2021): eabh3032.
84. Richardson P J., et al. “The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19”. Vaccines (Basel)6 (2022).
85. Marconi VC., et al. “Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial”. Lancet Respiratory Medicine12 (2021): 1407-1418.
86. Chen HF., et al. “Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2”. American Journal of Cancer Research 7 (2022): 3333-3346.
87. Cao B., et al. “A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19”. The New England Journal of Medicine 19 (2020): 1787-1799.

Citation

Citation: Bandoo C Chatale., et al. “From Discovery to Deployment: The Evolution of COVID-19 Treatment and Vaccination Strategies".Acta Scientific Microbiology 8.3 (2025): 75-88.

Copyright

Copyright: © 2025 Bandoo C Chatale., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.